Nolvadex 20mg

Dragon Pharma Nolvadex — Tamoxifen Citrate 20mg SERM

Dragon Pharma Nolvadex delivers 20 mg of Tamoxifen Citrate per tablet. This selective estrogen receptor modulator is the cornerstone of effective Post-Cycle Therapy and on-cycle gynecomastia management.

Unlike aromatase inhibitors that suppress estrogen synthesis, this agent competes directly with estradiol for receptor binding. It blocks estrogenic signaling in breast tissue and the hypothalamus while preserving favorable lipid profiles.

Overview

Tamoxifen Citrate is a triphenylethylene derivative with tissue-selective estrogen receptor antagonist and partial agonist activity. Its mechanism is distinct from steroidal and non-steroidal aromatase inhibitors.

In mammary tissue, Nolvadex functions as a pure antagonist. It prevents estradiol from activating growth pathways that lead to glandular proliferation and nipple sensitivity.

In the hypothalamus and pituitary, the compound blocks estrogen-mediated negative feedback. This triggers a compensatory release of gonadotropin-releasing hormone, luteinizing hormone, and follicle-stimulating hormone.

Elevated gonadotropins stimulate Leydig cell activity within the testes. This accelerates the restoration of endogenous testosterone and preserves muscular gains accrued during the anabolic phase.

Dragon Pharma subjects every production batch to independent analytical testing. Recent verification confirmed 21.05 mg per tablet, ensuring precise dosing for reliable PCT execution and gyno management.

Benefits

• Gynecomastia Prevention: Competes with estradiol for receptor occupancy in mammary tissue, halting glandular development and reversing early-stage nipple sensitivity.
• HPTA Reactivation: Blocks hypothalamic estrogen receptors, triggering a robust surge in GnRH, LH, and FSH to restart natural testosterone synthesis.
• Muscle Preservation: By rapidly restoring endogenous androgen support, it minimizes the catabolic tissue loss that typically follows exogenous hormone cessation.
• Favorable Lipid Profile: Unlike aromatase inhibitors, Tamoxifen exerts a neutral to positive effect on cholesterol, often supporting HDL levels during recovery.
• On-Cycle Versatility: Functions effectively as a prophylactic agent during active cycles for individuals genetically prone to estrogenic breast tissue development.

Main Features

• Precisely dosed 20 mg oral tablets for flexible titration
• Selective estrogen receptor modulator with tissue-specific activity
• Competitive antagonism at breast tissue estrogen receptors
• Hypothalamic blockade stimulating gonadotropin release
• Compatible with Clomid or Enclomiphene stacking for synergistic PCT
• Independent laboratory verification of tablet potency

Ingredients

Each tablet contains 20 mg of Tamoxifen Citrate as the active pharmaceutical ingredient.

Inactive excipients include corn starch, lactose, magnesium stearate, and pharmaceutical-grade binders to ensure tablet stability and consistent dissolution characteristics.

All raw materials undergo identity and purity validation prior to compression and film-coating.

How to Use

Ingest tablets with water, with or without food. Consistency in daily timing supports stable plasma concentrations throughout the protocol.

For Post-Cycle Therapy, initiate only after exogenous steroids have cleared systemic circulation. Long-estered compounds typically require a 14–21 day waiting period following the final injection.

Store the container in a cool, dry environment between 15–25°C (59–77°F). Protect from moisture and direct light. Keep the desiccant pouch intact.

Dosage

The standard 4-week PCT protocol begins with 40 mg daily for weeks 1–2. This loading phase delivers a powerful initial stimulus to the hypothalamic-pituitary-testicular axis.

Weeks 3–4 reduce to 20 mg daily. This maintenance dose sustains recovery momentum while the body's autonomous hormone production regains full function.

Following heavily suppressive cycles, an extended 6-week protocol may be beneficial. This utilizes 40 mg daily for weeks 1–2, followed by 20 mg daily for weeks 3–6.

For on-cycle gynecomastia prevention, 10–20 mg daily or every other day at the first sign of nipple sensitivity is typically sufficient. Existing early-stage gyno may respond to 20–40 mg daily until symptoms resolve.

Side Effects

Nolvadex can mildly suppress insulin-like growth factor 1 levels. This is an acceptable trade-off during recovery phases where hormonal restoration takes priority over anabolic growth.

Some users experience hot flashes reflecting the alteration in estrogen receptor signaling within thermoregulatory centers. These are typically mild and self-limiting.

Rare ocular disturbances including blurred vision or visual floaters have been reported. Discontinue immediately and seek ophthalmologic evaluation if any visual changes develop.

A very small increase in thromboembolic risk exists, though this is primarily associated with long-term therapeutic use rather than standard PCT durations.

Mood fluctuations and emotional sensitivity may occur during the post-cycle transition as hormone levels normalize. These typically resolve as endogenous production stabilizes.

Safety Information

This product is intended exclusively for research purposes and use by qualified male adults under appropriate supervision. It is not suitable for minors, pregnant or nursing women, or individuals with pre-existing thromboembolic or ocular conditions.

Ophthalmologic evaluation is recommended before initiating therapy. Any visual symptoms during the protocol require immediate cessation and professional assessment.

Stacking with Clomid or Enclomiphene produces superior recovery outcomes than Nolvadex alone. The combined SERM approach targets multiple pathways within the HPTA cascade.

Continue aromatase inhibitor therapy up until the first day of PCT. This prevents estrogen rebound as exogenous androgens clear, allowing SERMs to work more effectively.

Discontinue immediately and seek medical evaluation if severe visual disturbances, chest pain, shortness of breath, or unilateral leg swelling develop.